What comes after semaglutide and tirzepatide?
The pipeline of obesity medications is deeper than it has ever been. Triple-agonist compounds that hit GLP-1, GIP, and glucagon receptors simultaneously are reporting placebo-adjusted weight loss in the 15–24% range — beyond what current FDA-approved options deliver. Here is what is in Phase II and III trials.
What to do while you wait
You do not need to wait for the pipeline: approved options already work, and the best results come from pairing them with structured nutrition and follow-up. Get matched with a local provider who can discuss what is available today — and what the pipeline means for the future.
The short version
- Triple-agonist compounds that hit the GLP-1, GIP, and glucagon receptors simultaneously are reporting placebo-adjusted weight loss in the 15-24% range.
- That 15-24% range sits beyond the placebo-adjusted weight loss of current FDA-approved options, according to the article's summary of the pipeline.
- The compounds are in Phase II and Phase III trials, which means they are not yet available to patients.
- The advice while waiting is not to wait, because approved options already work best when paired with structured nutrition and follow-up.
